| Autor: |
Susanna, Gasparyan, Larisa, Drosova, Alesya, Khripunova, Sergey, Karpov, Irina, Vishlova |
| Předmět: |
|
| Zdroj: |
European Science Review; Mar/Apr2017, Issue 3/4, p45-48, 4p |
| Abstrakt: |
vasomotor symptoms are the most common symptoms of menopause, requiring treatment with estrogen or with progestogen. Recent international guidelines recognize the need to use the lowest effective dose of hormone replacement therapy. Drospirenone (DR) in combination with 17b-estradiol (E) is used as hormone therapy (HT) for relief the symptoms and prevention of postmenopausal osteoporosis. The review presents data of 2 large randomized controlled studies that evaluated the lowest effective dose combination of DR/E, the safety of this dose for endometrium, identified features of its pharmacodynamics and pharmacokinetics, depending on various factors. The minimum effective dose for the relief of HF without causing any significant impact on the endometrium is DR of 0,25 mg/E of 0,5 mg. According to the results of the pharmacokinetic study a correlation between effectiveness of low dose DR/E with DR and E exposure levels was showed, and smoking reduces the effectiveness of hormonal therapy. This drug not only copes with moderate to severe hot flashes, but also reduces the incidence of symptoms of vulvovaginal atrophy, improving quality of life. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
